Reported revenue rose from KRW 48.35 million in 2022 to KRW 324 million in 2023, KRW 3.36 billion in 2024, and KRW 3.7 billion in 2025. Revenue increased for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022 to 2025 period.
Revenue in 2024 rose 937.8% year on year, which the company attributed to expansion of its health functional food and pet businesses. Revenue in 2025 rose 10.0% year on year, and the company cited higher revenue from a merger completed during the year as the main driver.
Operating loss was KRW 9.51 billion in 2022, KRW 16.4 billion in 2023, KRW 18.9 billion in 2024, and KRW 15.8 billion in 2025, a loss in each of the four years from 2022, with the loss narrowing in 2025. The operating margin improved from -19,661.2% in 2022 to -428.4% in 2025, but costs still far exceed revenue.
Press reports on 2024 indicated that KRW 14.6 billion of the KRW 19.1 billion in selling and administrative expenses was R&D, so much of the loss stems from clinical investment.
Net loss attributable to controlling shareholders was KRW 10.6 billion in 2022, KRW 12.1 billion in 2023, KRW 29.4 billion in 2024, and KRW 16.3 billion in 2025, and the net loss including non-controlling interests was disclosed at the same amounts.
On a quarterly basis, revenue in the second quarter of 2026 was KRW 1.6 billion, up 67.4% from the prior quarter, before falling 33.1% to KRW 1.07 billion in the third quarter, so quarterly revenue is volatile.
The KRW 1.12 billion net profit attributable to controlling shareholders in the second quarter of 2026 came alongside an operating loss of KRW 3.57 billion, which suggests non-operating items had a large effect. The debt ratio fell from 7.1% in 2022 to 27.2% in 2025.
Operating cash flow was -KRW 6.83 billion in 2022, -KRW 14.1 billion in 2023, -KRW 12.2 billion in 2024, and -KRW 15.3 billion in 2025.